XSHG
688767
, Last price
Name
Hangzhou Biotest Biotech Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
0.44
Vol. 1Y
—
Shs. 5Y
5.48%
Rev. 5Y
-12.32%
Div Yld LY
—
Div Yld TTM
—
Revenues
448m
-19.85%
Net income
47m
-72.39%
CFO
106m
-17.35%
Dividend
Jun 01, 20260.7 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hangzhou Biotest Biotech Co., LTD. is an enterprise focused on the research, development, manufacturing, sales, and servicing of in vitro diagnostic (IVD) solutions. Operating both domestically within China and across international markets, the company provides a comprehensive range of medical testing products. Their offerings span crucial health areas including reproductive health, cancer detection, cardiovascular conditions, inflammatory markers, biochemical analysis, and various infectious diseases. This extensive portfolio also encompasses rapid diagnostic tests for COVID-19 (covering both antibody and antigen detection), as well as screening kits for drug use (utilizing urine, saliva, and hair samples) and assessing vitamin D levels. Beyond diagnostic kits and reagents, Hangzhou Biotest Biotech also supplies essential accompanying equipment, such as immunochromatography readers and fluorescence immunoassay quantitative analyzers. The company, established in 2008, is based in Hangzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||